The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Brawley to receive 2019 AMA Distinguished Service Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Otis Webb Brawley was named recipient of the 2019 AMA Distinguished Service Award by the American Medical Association board of trustees.

The award is the highest honor bestowed by AMA for “meritorious service in the science and art of medicine.”

Brawley is the Bloomberg Distinguished Professor of Oncology and Epidemiology at John Hopkins University Schools of Medicine and Public Health. He is a Fellow of the American Society of Clinical Oncology, a Fellow of the American College of Epidemiology, and a Master of the American College of Physicians. He is also an elected member of the National Academy of Medicine.

He is a former chief medical and scientific officer at the American Cancer Society, where he was involved in cancer prevention, early detection, and quality treatment through cancer research and education. He continues to champion efforts to decrease smoking, improve diet, detect cancer at the earliest stage, and provide the critical support cancer patients need.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.
By Jacquelyn Cobb and Sara Willa Ernst
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account